Five patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in May 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
2
Ending by 2030
May 2027
Next term end
2
Patent families
When these terms end
Each bar runs from grant to computed term end. 2013 to 2036.
US 11,058,714
Administration of Synergistic Amounts of Modified Citrus Pectin and Honokiol to Treat Inflammation and Anti-Oxidant Needs
Jun 14, 2036
US 11,596,647
Administration of Synergistic Amounts of Modified Citrus Pectin and Honokiol to Treat Inflammation and Anti-Oxidant Needs
Jun 17, 2036
20182023202820332036
Every computed term in this portfolio is shown above.Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends May 2027 · High confidence
Also notable
Ends Jun 2036 · High confidence
Binding of GALECTIN-3 by Low Molecular Weight Pectin
US 9,427,449
The largest patent family in this portfolio, 5 related applications, renewed at every maintenance window due so far. Protection runs to 2027.
Administration of Synergistic Amounts of Modified Citrus Pectin and Honokiol to Treat Inflammation and Anti-Oxidant Needs
US 11,058,714
Granted 2021. Computed term ends 2036.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Showing 1 to 5 of 5
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,427,449 | Binding of GALECTIN-3 by Low Molecular Weight Pectin In force · High confidence | In force | High confidence | |
| US 8,426,567 | Method for enhancing mammalian immunological function In force · High confidence | In force | High confidence | |
| US 8,916,541 | Anti-Cancer Regimen In force · High confidence | In force | High confidence | |
| US 11,058,714 | Administration of Synergistic Amounts of Modified Citrus Pectin and Honokiol to Treat Inflammation and Anti-Oxidant Needs In force · High confidence | In force | High confidence | |
| US 11,596,647 | Administration of Synergistic Amounts of Modified Citrus Pectin and Honokiol to Treat Inflammation and Anti-Oxidant Needs In force · High confidence | In force | High confidence |
Also on record, not counted in the 5: 4 patents ended · 4 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
2 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed
2 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.